ATE422357T1 - Verwendung von allopurinol zur behandlung von bluthochdruck - Google Patents

Verwendung von allopurinol zur behandlung von bluthochdruck

Info

Publication number
ATE422357T1
ATE422357T1 AT01946722T AT01946722T ATE422357T1 AT E422357 T1 ATE422357 T1 AT E422357T1 AT 01946722 T AT01946722 T AT 01946722T AT 01946722 T AT01946722 T AT 01946722T AT E422357 T1 ATE422357 T1 AT E422357T1
Authority
AT
Austria
Prior art keywords
allopurinol
treat hypertension
administering
patient
treatment
Prior art date
Application number
AT01946722T
Other languages
English (en)
Inventor
Salah Kivlighn
Richard Johnson
Marilda Mazzali
Original Assignee
Merck & Co Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Univ Washington filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE422357T1 publication Critical patent/ATE422357T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01946722T 2000-06-28 2001-06-28 Verwendung von allopurinol zur behandlung von bluthochdruck ATE422357T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21482500P 2000-06-28 2000-06-28

Publications (1)

Publication Number Publication Date
ATE422357T1 true ATE422357T1 (de) 2009-02-15

Family

ID=22800556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946722T ATE422357T1 (de) 2000-06-28 2001-06-28 Verwendung von allopurinol zur behandlung von bluthochdruck

Country Status (8)

Country Link
US (3) US7799794B2 (de)
EP (1) EP1317258B1 (de)
JP (1) JP2004517804A (de)
AT (1) ATE422357T1 (de)
AU (1) AU2001268734A1 (de)
CA (1) CA2413201A1 (de)
DE (1) DE60137635D1 (de)
WO (1) WO2002000210A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046724A1 (ja) * 2003-11-14 2005-05-26 Human Cell Systems, Inc. 血管障害や高血圧症の治療・予防剤、及びそのスクリーニング方法
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006012438A2 (en) 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
CA2607953A1 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CA2617161A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
JP5242393B2 (ja) * 2005-08-03 2013-07-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド 高血圧症の治療方法
EP1948183B1 (de) * 2005-10-13 2013-12-18 Duke University Zusammensetzungen zur behandlung und prävention von herzkrankheiten und anwendungsverfahren dafür
WO2008002911A2 (en) * 2006-06-26 2008-01-03 University Of Florida Research Foundation, Inc. Urate metabolites as diagnostic markers for cardiovascular and renal disease
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
EP2101761A4 (de) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A Verfahren zur konservierung der nierenfunktion mit xanthin-oxidoreductase-hemmern
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
EP2197550A1 (de) * 2007-09-05 2010-06-23 Sanofi-Aventis Verwendung von uratoxidase zur behandlung oder prophylaxe von erkrankungen oder indirekten folgen am herz durch ischämische oder reperfusionsereignisse
JP2012505925A (ja) * 2008-10-19 2012-03-08 リチャード ジェイ ジョンソン 代謝不均衡に関連付けられる慢性腎疾患を治療するための治療組成物及び方法
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
JP5405140B2 (ja) * 2009-02-16 2014-02-05 花王株式会社 アディポネクチン増加剤
WO2010150921A1 (ja) * 2009-06-26 2010-12-29 帝人ファーマ株式会社 高血圧症または正常高値血圧症の治療薬
JP2011098896A (ja) * 2009-11-04 2011-05-19 Kirin Holdings Co Ltd 尿酸値低下用組成物
WO2012033720A1 (en) * 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
ES2532210T3 (es) 2010-09-10 2015-03-25 Takeda Pharmaceuticals U.S.A., Inc. Métodos para el tratamiento concomitante de teofilina y febuxostat
US10806711B2 (en) 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
JP2016512564A (ja) 2013-03-13 2016-04-28 ユニバーシティ・オブ・シンシナティ Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
EP4681719A3 (de) 2013-03-15 2026-04-15 XORTX Therapeutics Inc. Xanthinoxidasehemmerformulierungen
US10548911B2 (en) 2014-06-16 2020-02-04 University Of Rochester Small molecule anti-scarring agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7017486A (de) * 1969-12-15 1971-06-17
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
SE412587B (sv) 1973-12-04 1980-03-10 Merck & Co Inc Forfarande for framstellning av substituerade imidazoler
US4296122A (en) 1975-07-09 1981-10-20 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids
DE2707270A1 (de) 1977-02-19 1978-08-24 Hoechst Ag Pyrazolo-diazepine und verfahren zu ihrer herstellung
DE2707269A1 (de) * 1977-02-19 1978-08-24 Hoechst Ag Heterocyclische stickstoffverbindungen und verfahren zu ihrer herstellung
DE2727802A1 (de) * 1977-06-21 1979-04-19 Hoechst Ag Sulfamoyl-arylketone und verfahren zu ihrer herstellung
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
DE3232922A1 (de) * 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Sulfamoylbenzophenon-derivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
DE3235565A1 (de) * 1982-09-25 1984-03-29 Boehringer Ingelheim KG, 6507 Ingelheim Piperidinderivate, ihre herstellung und verwendung
US4883821A (en) 1988-04-13 1989-11-28 Eisai Co., Ltd. Agent for treating hyperuricemia
JPH0366669A (ja) * 1989-08-03 1991-03-22 Shionogi & Co Ltd 複素環式化合物
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE69224069T2 (de) 1991-09-09 1998-07-02 Warner-Lambert Co., Ann Arbor, Mich. Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
DK9200258U4 (da) * 1992-03-11 1993-07-23 Merck & Co Inc Farmaceutisk præparat indeholdende enalapril til brug mod hypertension
JP3883205B2 (ja) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
CA2183834C (en) * 1995-08-22 2003-09-09 Hiroshi Maeda Antihypertensive agents containing pyrazolopyrimidine derivatives
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
WO1999024038A1 (en) * 1997-11-07 1999-05-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
EP1100542B1 (de) * 1998-08-06 2005-06-22 Mountain View Pharmaceuticals, Inc. Peg-uricase konjugate und verwendung davon

Also Published As

Publication number Publication date
US20020019360A1 (en) 2002-02-14
JP2004517804A (ja) 2004-06-17
DE60137635D1 (de) 2009-03-26
EP1317258A2 (de) 2003-06-11
AU2001268734A1 (en) 2002-01-08
US20090130078A1 (en) 2009-05-21
US20070232551A1 (en) 2007-10-04
US7799794B2 (en) 2010-09-21
CA2413201A1 (en) 2002-01-03
EP1317258B1 (de) 2009-02-11
WO2002000210A2 (en) 2002-01-03
WO2002000210A3 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60113548D1 (de) Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60128540D1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
ATE382354T1 (de) Präoperative behandlung von postoperativen schmerzen
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
AU2003283227A8 (en) Method and means for the treatment of vascular and cardiac diseases
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen
SE0100873D0 (sv) Method of treatment
NO20024545D0 (no) Fremgangsmåte for behandling av kongestiv hjertefeil
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties